Protalix BioTherapeutics Statistics
Share Statistics
Protalix BioTherapeutics has 79.61M
shares outstanding. The number of shares has increased by 6.43%
in one year.
| Shares Outstanding | 79.61M |
| Shares Change (YoY) | 6.43% |
| Shares Change (QoQ) | 5.97% |
| Owned by Institutions (%) | 6.07% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 228 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 995.48K, so 1.25% of the outstanding
shares have been sold short.
| Short Interest | 995.48K |
| Short % of Shares Out | 1.25% |
| Short % of Float | 1.31% |
| Short Ratio (days to cover) | 1.18 |
Valuation Ratios
The PE ratio is 46.51 and the forward
PE ratio is 1.97.
Protalix BioTherapeutics's PEG ratio is
-0.7.
| PE Ratio | 46.51 |
| Forward PE | 1.97 |
| PS Ratio | 2.55 |
| Forward PS | 1 |
| PB Ratio | 3.16 |
| P/FCF Ratio | 18.45 |
| PEG Ratio | -0.7 |
Financial Ratio HistoryEnterprise Valuation
Protalix BioTherapeutics has an Enterprise Value (EV) of 122.12M.
| EV / Sales | 2.29 |
| EV / EBITDA | 18.73 |
| EV / EBIT | 14.08 |
| EV / FCF | 16.52 |
Financial Position
The company has a current ratio of 2.34,
with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.34 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.85 |
| Debt / FCF | 0.75 |
| Interest Coverage | 3.69 |
Financial Efficiency
Return on Equity is 6.79% and Return on Invested Capital is 5.61%.
| Return on Equity | 6.79% |
| Return on Assets | 3.99% |
| Return on Invested Capital | 5.61% |
| Revenue Per Employee | $250,699.53 |
| Profits Per Employee | $13,765.26 |
| Employee Count | 213 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.14 |
Taxes
| Income Tax | 1.22M |
| Effective Tax Rate | 29.42% |
Stock Price Statistics
The stock price has increased by 45.61% in the
last 52 weeks. The beta is -0.05, so Protalix BioTherapeutics's
price volatility has been lower than the market average.
| Beta | -0.05 |
| 52-Week Price Change | 45.61% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 1.8 |
| Relative Strength Index (RSI) | 30.94 |
| Average Volume (20 Days) | 933,893 |
Income Statement
In the last 12 months, Protalix BioTherapeutics had revenue of 53.4M
and earned 2.93M
in profits. Earnings per share was 0.04.
| Revenue | 53.4M |
| Gross Profit | 29.08M |
| Operating Income | 3.92M |
| Net Income | 2.93M |
| EBITDA | 6.52M |
| EBIT | 5.22M |
| Earnings Per Share (EPS) | 0.04 |
Full Income StatementBalance Sheet
The company has 19.76M in cash and 5.53M in
debt, giving a net cash position of 14.23M.
| Cash & Cash Equivalents | 19.76M |
| Total Debt | 5.53M |
| Net Cash | 14.23M |
| Retained Earnings | -378.39M |
| Total Assets | 73.89M |
| Working Capital | 36.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 8.67M
and capital expenditures -1.28M, giving a free cash flow of 7.39M.
| Operating Cash Flow | 8.67M |
| Capital Expenditures | -1.28M |
| Free Cash Flow | 7.39M |
| FCF Per Share | 0.1 |
Full Cash Flow StatementMargins
Gross margin is 54.46%, with operating and profit margins of 7.34% and 5.49%.
| Gross Margin | 54.46% |
| Operating Margin | 7.34% |
| Pretax Margin | 7.78% |
| Profit Margin | 5.49% |
| EBITDA Margin | 12.21% |
| EBIT Margin | 7.34% |
| FCF Margin | 13.84% |
